


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (original): A compound represented by Formula I:



wherein  $R^1$  and  $R^2$  are independently chosen from hydrogen or an alkyl group;

$R^3$  and  $R^4$  are independently hydrogen or an alkyl group or;

$R^3$  and  $R^4$  and the carbon atom to which they are attached form a cycloalkyl ring, or;

$R^2$  and  $R^3$  together form a saturated  $(CH_2)_m$  heterocycle;

$R^5$  is hydrogen, halogen, or a substituted or unsubstituted alkyl group;

$R^6$  and  $R^7$  are independently hydrogen, halogen, cyano, an alkylthio, or a substituted or unsubstituted alkyl group;

$R^8$  and  $R^9$  are independently hydrogen, hydroxyl, a substituted or unsubstituted alkyl group, an alkoxy,  $=O$ ,  $NR^{10}R^{11}$ ,  $OC(=O)NR^1R^2$ ,  $OC(=O)C_{1-4}$ alkyl, or an alkylthiol;

$R^{10}$  and  $R^{11}$  are independently hydrogen, a substituted or unsubstituted alkyl group,  $C(=O)C_{1-4}$ alkyl,  $C(=O)OC_{1-4}$ alkyl, or  $C(=O)NR^1R^2$  or  $R^{10}$  and  $R^{11}$  together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is  $(CH_2)_n$ ,  $C=O$ , or  $CHC_{1-4}$ alkyl;

B is either a single or a double bond, wherein when B is a double bond, R<sup>8</sup> and R<sup>9</sup> are selected from hydrogen, or a substituted or unsubstituted alkyl group;

m = 2-4;

n = 0-2;

X and Y are either N or C, wherein X and Y are different; and the dashed bonds denote a suitably appointed single and double bond.

Claim 2 (original): The compound of claim 1, wherein R<sup>2</sup> and R<sup>3</sup> form a saturated (CH<sub>2</sub>)<sub>m</sub> heterocycle.

Claim 3 (original): The compound of claim 1, wherein said R<sup>3</sup> and R<sup>4</sup> together form a cyclopropyl ring.

Claim 4 (original): The compound of claim 1, wherein R<sup>1</sup> and R<sup>2</sup> are independently chosen from hydrogen or C<sub>1-4</sub>alkyl;

R<sup>3</sup> and R<sup>4</sup> are independently chosen from hydrogen or C<sub>1-4</sub>alkyl, or R<sup>2</sup> and R<sup>3</sup> together form a saturated (CH<sub>2</sub>)<sub>m</sub> heterocycle;

R<sup>5</sup> is chosen from hydrogen, halogen, or C<sub>1-6</sub>alkyl;

R<sup>6</sup> and R<sup>7</sup> are independently chosen from hydrogen, halogen, cyano, C<sub>1-4</sub>alkylthio, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>alkyl substituted by halogen;

R<sup>8</sup> and R<sup>9</sup> are chosen from hydrogen, hydroxyl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, NR<sup>10</sup>R<sup>11</sup>, or C<sub>1-6</sub>alkyl substituted with halogen, hydroxyl, or NR<sup>10</sup>R<sup>11</sup>;

R<sup>10</sup> and R<sup>11</sup> are independently chosen from hydrogen or C<sub>1-4</sub>alkyl or C(=O)C<sub>1-4</sub>alkyl or R<sup>10</sup> and R<sup>11</sup> together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is (CH<sub>2</sub>)<sub>n</sub> or CHC<sub>1-4</sub>alkyl;

B is either a single or double bond, wherein when B is a double bond,  $R^8$  and  $R^9$  are selected from hydrogen,  $C_{1-4}$ alkyl, or  $C_{1-4}$ alkyl substituted by halogen, hydroxy, or  $NR^{10}R^{11}$ ;

$m = 3-4$ ;

$n = 1-2$ ; and

X and Y are either N or C, wherein X and Y cannot be the same; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 5 (original): The compound of claim 1, wherein  $R^1$  and  $R^2$  are independently chosen from hydrogen or  $C_{1-4}$ alkyl;

$R^3$  is  $C_{1-2}$ alkyl, or  $R^2$  and  $R^3$  together are  $(CH_2)_3$  to form pyrrolidine;

$R^4$  is hydrogen;

$R^5$  is chosen from hydrogen or  $C_{1-6}$ alkyl;

$R^6$  and  $R^7$  are independently chosen from hydrogen, halogen, or  $C_{1-4}$ alkyl;

$R^8$  and  $R^9$  are independently chosen from hydrogen, hydroxyl,  $C_{1-6}$ alkoxy,  $NR^{10}R^{11}$ , or  $C_{1-6}$ alkyl substituted with hydroxyl or  $NR^{10}R^{11}$ ;

$R^{10}$  and  $R^{11}$  are independently chosen from hydrogen,  $C_{1-4}$ alkyl or  $C(=O)C_{1-4}$ alkyl or  $R^{10}$  and  $R^{11}$  together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is  $(CH_2)_n$ ;

B is a single bond;

$n = 1$ ;

X is C and Y is N; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 6 (original): The compound of claim 1, wherein said compound is:

1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;  
1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;  
(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;  
(S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;  
1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;  
1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;  
(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ylamine;  
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-yl]-dimethylamine;  
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-yl]-methanol;  
1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazole-8,9-diol;  
1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-*g*]indazol-8-ol;  
1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;  
1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol; or combinations thereof.

Claim 7 (original): The compound of claim 1, wherein said X is N.

Claim 8 (original): The compound of claim 1, wherein said X is C.

Claim 9 (original): A method of controlling normal or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one compound of claim 1.

Claim 10 (original): The method of claim 9, wherein  $R^2$  and  $R^3$  form a saturated  $(CH_2)_m$  heterocycle.

Claim 11 (original): The method of claim 9, wherein said  $R^3$  and  $R^4$  together form a cyclopropyl ring.

Claim 12 (original): The method of claim 9, wherein  $R^1$  and  $R^2$  are independently chosen from hydrogen or  $C_{1-4}$ alkyl;

$R^3$  and  $R^4$  are independently chosen from hydrogen or  $C_{1-4}$ alkyl, or  $R^2$  and  $R^3$  together form a saturated  $(CH_2)_m$  heterocycle;

$R^5$  is chosen from hydrogen, halogen, or  $C_{1-6}$ alkyl;

$R^6$  and  $R^7$  are independently chosen from hydrogen, halogen, cyano,  $C_{1-4}$ alkylthio,  $C_{1-4}$ alkyl, or  $C_{1-4}$ alkyl substituted by halogen;

$R^8$  and  $R^9$  are chosen from hydrogen, hydroxyl,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $NR^{10}R^{11}$ , or  $C_{1-6}$ alkyl substituted with halogen, hydroxyl, or  $NR^{10}R^{11}$ ;

$R^{10}$  and  $R^{11}$  are independently chosen from hydrogen or  $C_{1-4}$ alkyl or  $C(=O)C_{1-4}$ alkyl or  $R^{10}$  and  $R^{11}$  together can complete a saturated 5 or 6-membered heterocyclic ring, which can include an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is  $(CH_2)_n$  or  $CHC_{1-4}$ alkyl;

B is either a single or double bond, wherein when B is a double bond,  $R^8$  and  $R^9$  are selected from hydrogen,  $C_{1-4}$ alkyl, or  $C_{1-4}$ alkyl substituted by halogen, hydroxy, or  $NR^{10}R^{11}$ ;

$m = 3-4$ ;

$n = 1-2$ ; and

X and Y are either N or C, wherein X and Y cannot be the same; and  
the dashed bonds denote a suitably appointed single and double bond.

Claim 13 (original): The method of claim 9, wherein  $R^1$  and  $R^2$  are independently chosen from hydrogen or  $C_{1-4}$ alkyl;

$R^3$  is  $C_{1-2}$ alkyl, or  $R^2$  and  $R^3$  together are  $(CH_2)_3$  to form pyrrolidine;

$R^4$  is hydrogen;

$R^5$  is chosen from hydrogen or  $C_{1-6}$ alkyl;

$R^6$  and  $R^7$  are independently chosen from hydrogen, halogen, or  $C_{1-4}$ alkyl;

$R^8$  and  $R^9$  are independently chosen from hydrogen, hydroxyl,  $C_{1-6}$ alkoxy,  $NR^{10}R^{11}$ , or  $C_{1-6}$ alkyl substituted with hydroxyl or  $NR^{10}R^{11}$ ;

$R^{10}$  and  $R^{11}$  are independently chosen from hydrogen,  $C_{1-4}$ alkyl or  $C(=O)C_{1-4}$ alkyl or  $R^{10}$  and  $R^{11}$  together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is  $(CH_2)_n$ ;

B is a single bond;

$n = 1$ ;

X is C and Y is N; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 14 (original): The method of claim 9, wherein said compound is:

1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
(S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ylamine;  
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-dimethylamine;  
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-methanol;  
1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazole-8,9-diol;  
1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;  
1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol; or combinations thereof.

Claim 15 (original): The method of claim 9, wherein said X is N.

Claim 16 (original): The method of claim 9, wherein said X is C.

Claim 17 (original): A method for the treatment of glaucoma comprising administering a pharmaceutically effective amount of a composition comprising at least one compound of claim 1.

Claim 18 (original): The method of claim 17, wherein R<sup>1</sup> and R<sup>2</sup> are independently chosen from hydrogen or C<sub>1-4</sub>alkyl;

R<sup>3</sup> and R<sup>4</sup> are independently chosen from hydrogen or C<sub>1-4</sub>alkyl, or R<sup>2</sup> and R<sup>3</sup> together form a saturated (CH<sub>2</sub>)<sub>m</sub> heterocycle;

R<sup>5</sup> is chosen from hydrogen, halogen, or C<sub>1-6</sub>alkyl;

R<sup>6</sup> and R<sup>7</sup> are independently chosen from hydrogen, halogen, cyano, C<sub>1-4</sub>alkylthio, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>alkyl substituted by halogen;

$R^8$  and  $R^9$  are chosen from hydrogen, hydroxyl,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $NR^{10}R^{11}$ , or  $C_{1-6}$ alkyl substituted with halogen, hydroxyl, or  $NR^{10}R^{11}$ ;

$R^{10}$  and  $R^{11}$  are independently chosen from hydrogen or  $C_{1-4}$ alkyl or  $C(=O)C_{1-4}$ alkyl or  $R^{10}$  and  $R^{11}$  together can complete a saturated 5 or 6-membered heterocyclic ring, which can include an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is  $(CH_2)_n$  or  $CHC_{1-4}$ alkyl;

B is either a single or double bond, wherein when B is a double bond,  $R^8$  and  $R^9$  are selected from hydrogen,  $C_{1-4}$ alkyl, or  $C_{1-4}$ alkyl substituted by halogen, hydroxy, or  $NR^{10}R^{11}$ ;

$m = 3-4$ ;

$n = 1-2$ ; and

X and Y are either N or C, wherein X and Y cannot be the same; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 19 (original): The method of claim 17, wherein  $R^1$  and  $R^2$  are independently chosen from hydrogen or  $C_{1-4}$ alkyl;

$R^3$  is  $C_{1-2}$ alkyl, or  $R^2$  and  $R^3$  together are  $(CH_2)_3$  to form pyrrolidine;

$R^4$  is hydrogen;

$R^5$  is chosen from hydrogen or  $C_{1-6}$ alkyl;

$R^6$  and  $R^7$  are independently chosen from hydrogen, halogen, or  $C_{1-4}$ alkyl;

$R^8$  and  $R^9$  are independently chosen from hydrogen, hydroxyl,  $C_{1-6}$ alkoxy,  $NR^{10}R^{11}$ , or  $C_{1-6}$ alkyl substituted with hydroxyl or  $NR^{10}R^{11}$ ;

$R^{10}$  and  $R^{11}$  are independently chosen from hydrogen,  $C_{1-4}$ alkyl or  $C(=O)C_{1-4}$ alkyl or  $R^{10}$  and  $R^{11}$  together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;



A is (CH<sub>2</sub>)<sub>n</sub>;

B is a single bond;

n = 1;

X is C and Y is N; and

the dashed bonds denote a suitably appointed single and double bond.

Claim 20 (original): The method of claim 17, wherein said compound is:

1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
(S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ylamine;  
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-dimethylamine;  
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-methanol;  
1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazole-8,9-diol;  
1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;  
1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;  
1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;  
1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol; or combinations thereof.

Preliminary Amendment

U.S. Patent Application No. Unassigned

Claim 21 (original): A pharmaceutical composition comprising the compound of claim 1 and at least one carrier.

Claim 22 (currently amended): A method to ~~block~~ activate or bind to serotonin receptors comprising administering an effective amount of at least one compound of claim 1 to a patient.